SYS6010 injection

DRUG2 trials

Sponsors

CSPC Megalith Biopharmaceutical Co.,Ltd.

Conditions

Head and Neck Squamous Cell CarcinomaNon-Small Cell Lung Cancer

Phase 2

SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

RecruitingNCT07254585

CSPC Megalith Biopharmaceutical Co.,Ltd.Head and Neck Squamous Cell Carcinoma

Start: 2025-12-18End: 2027-12-31Target: 70Updated: 2026-01-26

Phase 3

SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）

Not yet recruitingNCT07633873

CSPC Megalith Biopharmaceutical Co.,Ltd.Non-Small Cell Lung Cancer

Start: 2026-06-02End: 2029-05-30Target: 500Updated: 2026-06-11